Today's Trend
FibroGen, Inc. (NASDAQ: FGEN) — shares are trading lower today following a batch of analyst model revisions. Investors are reacting to mixed analyst moves: William Blair narrowed projected losses across multiple quarters and years (a constructive sign), while HC Wainwright made some cuts to near‑term estimates (a cautionary signal). Below are the items most likely driving the stock.
- William Blair raised its EPS forecasts across multiple 2025–2027 periods, trimming expected quarterly losses (e.g., Q1–Q4 2026 and Q3 2026 were revised to smaller losses) and improving FY2026 and FY2027 outlooks — a reduction in expected losses can be viewed positively for the company’s forward trajectory. MarketBeat: William Blair revisions
- HC Wainwright reiterated a "Buy" rating and a $43 price target, which supports upside sentiment but may be discounted given the large variance in forecasts. MarketBeat: HC Wainwright note
- Analyst views diverge sharply from consensus (the consensus full‑year estimate cited is far less negative), creating uncertainty — conflicting models often increase short‑term volatility rather than produce a clear directional move. MarketBeat: Analyst consensus context
- HC Wainwright trimmed its Q4 2025 and FY2025 EPS estimates (raising near‑term expected losses), signaling weaker near‑term performance than previously thought — that contributed downward pressure on the share price. MarketBeat: HC Wainwright cuts
- Despite the upgrades, all post‑revision forecasts still imply substantial multi‑year losses (FY2026 and FY2027 projections remain deeply negative), keeping valuation risk high and limiting near‑term upside. MarketBeat: Long‑term loss outlook
Bottom line for investors: mixed analyst revisions — William Blair’s narrower-loss revisions are constructive, but HC Wainwright’s near‑term cuts and the still‑large projected losses increase uncertainty. That combination is a likely driver of today’s downward price movement.